Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Eagle Pharmaceutical (EGRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 674,528
  • Shares Outstanding, K 14,913
  • Annual Sales, $ 236,710 K
  • Annual Income, $ 51,940 K
  • 36-Month Beta 1.69
  • Price/Sales 3.44
  • Price/Cash Flow 11.24
  • Price/Book 3.33

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 0.79
  • Number of Estimates 1
  • High Estimate 0.79
  • Low Estimate 0.79
  • Prior Year 0.84
  • Growth Rate Est. (year over year) -5.95%

Price Performance

See More
Period Period Low Period High Performance
1-Month
38.38 +19.96%
on 02/11/19
46.69 -1.39%
on 02/21/19
+4.00 (+9.51%)
since 01/22/19
3-Month
36.03 +27.78%
on 12/24/18
51.41 -10.45%
on 12/03/18
-2.65 (-5.44%)
since 11/21/18
52-Week
36.03 +27.78%
on 12/24/18
85.66 -46.25%
on 07/20/18
-18.98 (-29.19%)
since 02/22/18

Most Recent Stories

More News
Eagle Pharmaceuticals to Discuss Fourth Quarter and Full Year 2018 Financial Results on February 28, 2019

Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (Nasdaq: EGRX) today announced that the Company will release its 2018 fourth quarter and full year financial results on Thursday, February...

EGRX : 45.71 (+1.04%)
Earnings Preview: Eagle Pharmaceuticals (EGRX) Q4 Earnings Expected to Decline

Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EGRX : 45.71 (+1.04%)
Should Value Investors Buy Eagle Pharmaceuticals (EGRX) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

EGRX : 45.71 (+1.04%)
Shares of EGRX Down 45.7% Since Downtrend Call on Shares

SmarTrend identified a Downtrend for Eagle Pharmaceut (NASDAQ:EGRX) on August 2nd, 2018 at $76.78. In approximately 6 months, Eagle Pharmaceut has returned 45.71% as of today's recent price of $41.68....

EGRX : 45.71 (+1.04%)
Shares of EGRX Down 46.7% Since Downtrend Call on Shares

SmarTrend identified a Downtrend for Eagle Pharmaceut (NASDAQ:EGRX) on August 2nd, 2018 at $76.78. In approximately 5 months, Eagle Pharmaceut has returned 46.69% as of today's recent price of $40.93....

EGRX : 45.71 (+1.04%)
Eagle Pharmaceuticals, Inc. to Present at 37th Annual J.P. Morgan Healthcare Conference

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at...

JPM : 105.38 (-0.09%)
EGRX : 45.71 (+1.04%)
47.5% Return Seen to Date on SmarTrend Eagle Pharmaceut Call (EGRX)

SmarTrend identified a Downtrend for Eagle Pharmaceut (NASDAQ:EGRX) on August 2nd, 2018 at $76.78. In approximately 5 months, Eagle Pharmaceut has returned 47.52% as of today's recent price of $40.29....

EGRX : 45.71 (+1.04%)
Eagle Pharmaceut Shares Down 52.1% Since SmarTrend's Sell Call (EGRX)

SmarTrend identified a Downtrend for Eagle Pharmaceut (NASDAQ:EGRX) on August 2nd, 2018 at $76.78. In approximately 5 months, Eagle Pharmaceut has returned 52.15% as of today's recent price of $36.74....

EGRX : 45.71 (+1.04%)
Corelogic Inc Has Returned 24.8% Since SmarTrend Recommendation (CLGX)

SmarTrend identified a Downtrend for Corelogic Inc (NYSE:CLGX) on July 26th, 2018 at $51.30. In approximately 4 months, Corelogic Inc has returned 24.83% as of today's recent price of $38.56.

CTT : 9.80 (+0.31%)
EPAY : 48.91 (+1.79%)
EXAS : 90.48 (+8.65%)
WYNN : 131.49 (+1.43%)
HMSY : 34.34 (+9.92%)
GLT : 14.01 (-0.57%)
MHK : 140.82 (+0.56%)
BBW : 5.17 (+0.39%)
CDW : 95.71 (+0.75%)
COUP : 94.28 (+2.17%)
QTWO : 67.29 (+1.55%)
DENN : 18.12 (+1.46%)
MYL : 31.26 (+0.64%)
DFRG : 8.87 (-0.34%)
GCAP : 7.18 (-0.83%)
FEYE : 16.74 (+1.15%)
MXIM : 55.84 (+1.05%)
POL : 33.82 (+0.71%)
AN : 36.75 (-4.25%)
TWO : 13.94 (+1.09%)
HUBG : 44.72 (-2.97%)
AR : 9.73 (+0.41%)
RE : 223.99 (+0.53%)
NNBR : 10.70 (+0.19%)
ARE : 136.81 (+0.97%)
CVI : 43.27 (+4.49%)
CERS : 6.57 (-0.45%)
NDAQ : 88.66 (+0.67%)
ELLI : 99.02 (-0.13%)
BLDR : 14.01 (+1.16%)
EGRX : 45.71 (+1.04%)
RGLD : 90.71 (+0.91%)
PRGO : 48.72 (+0.83%)
PENN : 24.91 (+3.45%)
NTAP : 65.89 (+0.69%)
IBM : 138.91 (+0.78%)
NTRI : 43.44 (-0.05%)
BANR : 63.55 (+0.24%)
CWT : 52.56 (+1.10%)
STAA : 36.22 (-1.82%)
ATHN : 134.99 (+0.01%)
CL : 66.83 (+0.19%)
TFSL : 17.37 (+1.58%)
UFPI : 32.50 (-0.03%)
SDRL : 8.56 (+0.82%)
GOV : 6.87 (-5.50%)
HQY : 80.17 (+1.01%)
IPGP : 156.09 (+1.32%)
MINI : 35.72 (-0.11%)
CMTL : 27.14 (-0.04%)
CHD : 66.35 (+0.30%)
GPI : 62.85 (+1.27%)
HRL : 42.62 (+1.50%)
RARE : 59.43 (+2.01%)
MLI : 33.92 (+0.89%)
GPS : 24.73 (-0.20%)
CHS : 5.52 (+2.79%)
RYAM : 14.80 (-1.46%)
PBI : 8.24 (+17.21%)
NUVA : 58.06 (+1.38%)
IMDZ : 5.82 (unch)
CAMP : 14.55 (+1.25%)
NOC : 288.13 (+0.22%)
AEL : 33.31 (+1.46%)
EBIX : 59.01 (+0.27%)
DISCA : 29.26 (+0.90%)
GPOR : 8.02 (+0.88%)
BGS : 25.96 (-4.42%)
TECH : 194.73 (+0.40%)
PCH : 37.15 (+0.98%)
NOV : 28.72 (-0.14%)
TECD : 106.41 (-0.06%)
DISCK : 27.55 (+0.92%)
DECK : 145.14 (+1.31%)
NOW : 234.37 (+1.90%)
MGLN : 71.08 (+0.82%)
IEX : 143.75 (+0.91%)
PTC : 92.33 (+0.69%)
AVT : 44.99 (+0.54%)
RGS : 18.14 (+0.11%)
BSFT : 54.95 (+0.09%)
FOSL : 15.75 (+3.96%)
WAL : 46.58 (+0.15%)
IVR : 15.94 (+0.19%)
ENR : 46.17 (+0.11%)
ISBC : 12.72 (-0.08%)
SHOO : 32.57 (+0.03%)
HDP : 14.68 (+1.80%)
AWK : 101.12 (+0.74%)
OMED : 0.90 (+2.27%)
LADR : 18.25 (+0.44%)
BIG : 31.08 (-1.08%)
WY : 26.12 (+1.48%)
JBLU : 17.31 (-1.03%)
GNMK : 7.65 (+12.17%)
FORM : 16.26 (+1.18%)
PFSI : 24.25 (+1.13%)
NEWM : 14.01 (+1.97%)
KFRC : 38.68 (+0.62%)
HOLX : 46.83 (+0.82%)
TMK : 83.13 (-0.08%)
AXTA : 27.23 (+0.89%)
PGEM : 21.65 (unch)
CLH : 59.89 (-0.84%)
CLI : 21.46 (-1.11%)
NRG : 42.34 (-0.28%)
CLGX : 40.14 (+0.63%)
SFLY : 45.66 (-1.25%)
ICUI : 253.32 (+0.13%)
CARA : 16.99 (+2.10%)
WTR : 36.18 (+0.89%)
NTGR : 35.57 (+2.71%)
OLED : 145.42 (+22.74%)
VNDA : 21.07 (+5.19%)
HIBB : 17.60 (-0.28%)
FFBC : 28.20 (-0.04%)
DLTR : 97.25 (-0.89%)
EQT : 19.60 (+3.00%)
OMER : 14.40 (+3.23%)
KTOS : 17.39 (-1.31%)
SRCL : 45.36 (+0.69%)
GES : 21.12 (+0.24%)
KMX : 61.06 (-0.75%)
PLAB : 10.48 (-0.10%)
NCS : 7.14 (+0.99%)
MAR : 128.77 (+1.10%)
MRVL : 19.65 (+0.20%)
UAL : 89.52 (+0.77%)
CNK : 38.40 (+4.07%)
NATH : 73.31 (-0.41%)
TPH : 13.37 (+1.13%)
OCUL : 4.15 (+14.96%)
SKYW : 55.69 (+0.69%)
HIVE : 4.74 (-1.04%)
GAIA : 11.70 (-0.17%)
ESRX : 92.33 (-3.62%)
PHM : 28.03 (+1.56%)
EBS : 64.51 (+1.24%)
CACI : 183.46 (+0.80%)
SAVE : 59.65 (+0.12%)
EZPW : 10.35 (+1.07%)
TPX : 58.19 (-0.53%)
KLAC : 115.03 (+1.81%)
ULTA : 309.57 (+0.50%)
WWE : 86.37 (-0.13%)
ESV : 4.47 (-1.54%)
LTRPA : 16.26 (+2.33%)
DAL : 51.43 (-0.10%)
BMY : 50.72 (+1.18%)
ECL : 166.97 (-0.07%)
CHRW : 91.84 (-0.37%)
WWW : 35.68 (-0.94%)
ETH : 19.65 (+0.77%)
IART : 54.41 (-2.11%)
LE : 17.65 (+2.50%)
LH : 148.58 (+0.18%)
HZO : 18.72 (-1.63%)
MTD : 676.05 (+0.27%)
OSTK : 19.81 (-0.95%)
LDOS : 64.28 (+2.11%)
SAGE : 152.61 (+4.40%)
CIEN : 43.32 (+2.29%)
MTW : 19.01 (+2.26%)
AMC : 13.94 (+1.75%)
NDLS : 8.12 (+8.99%)
EFII : 27.22 (+0.11%)
SIVB : 245.08 (-0.23%)
MU : 42.39 (+2.07%)
DSW : 28.17 (+0.82%)
VRNT : 53.40 (+1.64%)
OII : 15.88 (-0.50%)
SAFM : 118.95 (-1.42%)
DATA : 131.99 (+1.22%)
TLYS : 11.79 (+0.86%)
TREE : 321.06 (+3.50%)
TRUP : 29.64 (-0.60%)
AMCX : 64.36 (+0.97%)
EXPD : 75.93 (+0.54%)
SUPN : 36.61 (-0.05%)
NBIX : 78.77 (+1.89%)
SAIC : 76.41 (+0.91%)
CBM : 39.80 (-0.97%)
BURL : 163.83 (+0.48%)
AMED : 128.19 (+1.17%)
EXPR : 5.09 (-0.39%)
SBH : 17.96 (+0.50%)
ATSG : 25.30 (-0.51%)
PLT : 50.29 (+1.47%)
QDEL : 67.29 (+0.18%)
NLNK : 1.65 (-10.81%)
STMP : 84.80 (-57.19%)
IPCC : 142.80 (+0.32%)
BMTC : 40.61 (+0.02%)
STML : 11.51 (-0.35%)
EGL : 29.10 (+0.24%)
LUV : 53.61 (-1.29%)
CCL : 58.66 (+0.67%)
INOV : 13.22 (-1.86%)
COTY : 11.20 (+0.81%)
MGM : 27.63 (-2.54%)
AKBA : 7.07 (+8.94%)
LGIH : 62.32 (+1.32%)
CDNS : 56.35 (+1.71%)
CRZO : 11.88 (+0.08%)
TEN : 36.35 (+2.31%)
HAIN : 17.53 (-3.10%)
Analysis: Positioning to Benefit within Dicerna Pharmaceuticals, Sun Life Financial, Autodesk, Eagle Pharmaceuticals, Curis, and Accenture -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Dicerna Pharmaceuticals, Inc....

DRNA : 10.35 (-3.63%)
ADSK : 161.10 (+0.79%)
CRIS : 1.11 (-1.77%)
EGRX : 45.71 (+1.04%)
SLF : 37.79 (+0.53%)
ACN : 161.21 (+1.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade EGRX with:

Business Summary

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102,...

See More

Key Turning Points

2nd Resistance Point 47.97
1st Resistance Point 46.61
Last Price 45.71
1st Support Level 43.96
2nd Support Level 42.67

See More

52-Week High 85.66
Fibonacci 61.8% 66.70
Fibonacci 50% 60.85
Fibonacci 38.2% 54.99
Last Price 45.71
52-Week Low 36.03

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar